ClinicalTrials.gg
TerminatedNCT03979638RELIEFUpdated Aug 3, 2021Results posted

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

A Phase 2 interventional study of BLU-5937 and Placebo in Chronic Refractory Cough, sponsored by Bellus Health Inc. - a GSK company. Terminated at 16 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-08-03.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was terminated due to the impact of the COVID-19 on trial activities. 68 patients with refractory chronic cough were enrolled with 52 completing treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.

Enrollment
14th of 37
68 · median 50
Started
2019
with 2 others
Phase 2
16 of 44
3 open now
Registered
16th of 44
by date
Lead sponsor
4 of 44
Bellus Health Inc. - a GSK company

Among the 44 studies in Chronic Cough with a site in United States, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 2, and was the 16th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough

Read the detailed description

This study will have two 16-day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day follow-up period.

03

Conditions studied

  • Chronic Refractory Cough

Browse trials for

Keywords

  • Unexplained or refractory chronic cough, P2X3 antagonists
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unexplained or chronic cough for at least one year
  • Chest radiograph or CT thorax within the last 60 months not demonstrating any abnormality considered to be significantly contributing to the chronic cough
  • Cough count of ≥ 10 per hour (Awake Cough Count) at Screening
  • Score of ≥ 40mm on the Cough Severity VAS at Screening
  • Women of must have a negative serum pregnancy test at Screening
  • Women of child-bearing potential must use a highly effective method from Screening through the Follow-Up Visit
  • Male subjects and their partners of child-bearing potential must use 2 methods of acceptable birth control

Exclusion criteria

Exclusion Criteria:

  • Current smoker or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history
  • Diagnosis of , bronchiectasis, idiopathic pulmonary fibrosis
  • Treatment with an ACE-inhibitor as the potential cause of a subject's cough, or requiring treatment with an ACE-inhibitor during the study, or within 12 weeks prior to the Screening Visit
  • /FVC \< 60%
  • History of upper respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit
  • History of concurrent or recurrence of malignancy within 2 years prior to Screening
  • History of a diagnosis of drug or alcohol dependency or abuse within the last 3 years
  • abnormal (ECG) or laboratory tests at Screening
  • Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or product administration or may interfere with the interpretation of trial results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    BLU-5937 oral tablet BID

    Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID

    Drug: BLU-5937

  • Placebo comparator
    Placebo oral tablet BID

    Randomized crossover design of matching placebo tablets to be administered orally BID

    Drug: Placebo

Interventions

  • Four escalating doses of BLU-5937 administered BID over the course of the study

  • DrugPlacebo

    Matching placebo for BLU-5937

06

What researchers measure

Primary outcomes

  1. Change in Awake Objective Cough Frequency on Log-transformed Scale

    Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

    Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses

Other outcomes

  1. Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline

    Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

    Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses

  2. Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline

    Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

    Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12,16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses

07

Results

Posted Aug 3, 2021

Participant flow

Participants were recruited at 16 clinical trial sites in the United-Kingdom and in United States.

Period 1
Participant flow — Period 1
MilestoneBLU-5937 > PlaceboPlacebo > BLU-5937
Started3335
Completed2628
Not completed77
Withdrew: Physician decision11
Withdrew: Withdrawal by subject43
Withdrew: Study terminated by sponsor13
Withdrew: Protocol violation10
Period 2
Participant flow — Period 2
MilestoneBLU-5937 > PlaceboPlacebo > BLU-5937
Started2628
Completed2527
Not completed11
Withdrew: Study terminated by sponsor11

Outcome measures

PrimaryChange in Awake Objective Cough Frequency on Log-transformed Scale

Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

Time frame:
Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Reported as:
Least squares mean · Log coughs/hour
Change in Awake Objective Cough Frequency on Log-transformed Scale
Log coughs/hourBLU-5937 - 25 mgPlacebo Comparator - 25 mgBLU-5937 - 50 mgPlacebo Comparator - 50 mgBLU-5937 - 100 mgPlacebo Comparator - 100 mgBLU-5937 - 200 mgPlacebo Comparator - 200 mg
Change in Awake Objective Cough Frequency on Log-transformed Scale-0.19 (-0.29 to -0.08)-0.07 (-0.19 to 0.05)-0.20 (-0.32 to -0.08)-0.14 (-0.26 to -0.01)-0.25 (-0.40 to -0.09)-0.17 (-0.30 to -0.04)-0.33 (-0.49 to -0.17)-0.14 (-0.29 to 0.00)
Statistical analysis
  • BLU-5937 - 25 mg vs Placebo Comparator - 25 mg · Mixed Models Analysis · p = 0.1424 · Estimated percent change: -10.8 · 95% CI -23.5 to 4.0Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 50 mg vs Placebo Comparator - 50 mg · Mixed Models Analysis · p = 0.4602 · Estimated percent change: -6.1 · 95% CI -20.8 to 11.2Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 100 mg vs Placebo Comparator - 100 mg · Mixed Models Analysis · p = 0.4181 · Estimated percent change: -7.8 · 95% CI -24.4 to 12.5Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 200 mg vs Placebo Comparator - 200 mg · Mixed Models Analysis · p = 0.0855 · Estimated percent change: -16.7 · 95% CI -32.3 to 2.6Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
Other pre-specifiedChange in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline

Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

Time frame:
Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Reported as:
Least squares mean · Log coughs/hour
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline
Log coughs/hourBLU-5937 - 25 mgPlacebo Comparator - 25 mgBLU-5937 - 50 mgPlacebo Comparator - 50 mgBLU-5937 - 100 mgPlacebo Comparator - 100 mgBLU-5937 - 200 mgPlacebo Comparator - 200 mg
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline-0.23 (-0.34 to -0.11)0.00 (-0.09 to 0.10)-0.29 (-0.42 to -0.15)-0.09 (-0.21 to 0.03)-0.33 (-0.51 to -0.16)-0.12 (-0.25 to 0.01)-0.41 (-0.58 to -0.24)-0.09 (-0.23 to 0.05)
Statistical analysis
  • BLU-5937 - 25 mg vs Placebo Comparator - 25 mg · Mixed Models Analysis · p = 0.0010 · Estimated percent change: -20.3 · 95% CI -29.9 to -9.5Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 50 mg vs Placebo Comparator - 50 mg · Mixed Models Analysis · p = 0.0186 · Estimated percent change: -17.7 · 95% CI -29.9 to -3.3Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 100 mg vs Placebo Comparator - 100 mg · Mixed Models Analysis · p = 0.0320 · Estimated percent change: -19.4 · 95% CI -33.9 to -1.9Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 200 mg vs Placebo Comparator - 200 mg · Mixed Models Analysis · p = 0.0026 · Estimated percent change: -27.0 · 95% CI -40.3 to -10.8Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
Other pre-specifiedChange in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline

Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected

Time frame:
Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12,16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Reported as:
Least squares mean · Log coughs/hour
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline
Log coughs/hourBLU-5937 - 25 mgPlacebo Comparator - 25 mgBLU-5937 - 50 mgPlacebo Comparator - 50 mgBLU-5937 - 100 mgPlacebo Comparator - 100 mgBLU-5937 - 200 mgPlacebo Comparator - 200 mg
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline-0.31 (-0.45 to -0.18)0.02 (-0.11 to 0.15)-0.42 (-0.55 to -0.28)-0.08 (-0.22 to 0.05)-0.44 (-0.60 to -0.27)-0.09 (-0.24 to 0.06)-0.49 (-0.68 to -0.31)-0.10 (-0.24 to 0.03)
Statistical analysis
  • BLU-5937 - 25 mg vs Placebo Comparator - 25 mg · Mixed Models Analysis · p = 0.0005 · Estimated percent change: -28.1 · 95% CI -39.5 to -14.5Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 50 mg vs Placebo Comparator - 50 mg · Mixed Models Analysis · p = 0.0003 · Estimated percent change: -28.4 · 95% CI -39.7 to -15.0Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 100 mg vs Placebo Comparator - 100 mg · Mixed Models Analysis · p = 0.0014 · Estimated percent change: -29.5 · 95% CI -42.7 to -13.2Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.
  • BLU-5937 - 200 mg vs Placebo Comparator - 200 mg · Mixed Models Analysis · p = 0.0006 · Estimated percent change: -32.4 · 95% CI -45.3 to -16.4Percent change difference between BLU-5937 and placebo was estimated by 100 x \[e\^diff - 1\] where 'e' = exponent of difference; and 'diff' = the treatment mean difference from mixed model of change from baseline based on log-transformed data.

Adverse events

Collected over All-cause mortality and Adverse Event data collection is up to 11 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BLU-5937 - 25 mg0/61 (0%)0/61 (0%)10/61 (16.4%)
BLU-5937 - 50 mg0/61 (0%)0/61 (0%)14/61 (23%)
BLU-5937 - 100 mg0/60 (0%)0/60 (0%)15/60 (25%)
BLU-5937 - 200 mg0/58 (0%)0/58 (0%)10/58 (17.2%)
Placebo0/61 (0%)1/61 (1.6%)19/61 (31.1%)
Most frequent serious events
Most frequent serious events
EventBLU-5937 - 25 mgBLU-5937 - 50 mgBLU-5937 - 100 mgBLU-5937 - 200 mgPlacebo
colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)————1/61
Most frequent other events
Most frequent other events
EventBLU-5937 - 25 mgBLU-5937 - 50 mgBLU-5937 - 100 mgBLU-5937 - 200 mgPlacebo
HeadacheNervous system disorders3/612/614/603/587/61
Back painMusculoskeletal and connective tissue disorders2/613/612/601/586/61
DysgeusiaNervous system disorders3/615/615/604/582/61
Upper respiratory tract infectionInfections and infestations2/614/614/603/583/61
DizzinessNervous system disorders3/614/613/602/582/61
DiarrhoeaGastrointestinal disorders1/611/611/600/583/61

Baseline characteristics

The baseline analysis population consisted of all randomized participants who have received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)BLU-5937 > PlaceboPlacebo > BLU-5937Total
Mean64.3 ± 11.4963.7 ± 9.7064.0 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)BLU-5937 > PlaceboPlacebo > BLU-5937Total
Female283058
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BLU-5937 > PlaceboPlacebo > BLU-5937Total
Hispanic or Latino213
Not Hispanic or Latino293463
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BLU-5937 > PlaceboPlacebo > BLU-5937Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American011
White333366
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • Allergy Associates Medical Group Inc.
    San Diego, California 92108, United States
  • Allergy & Asthma Associates of Santa Clara Valley
    San Jose, California 95117, United States
  • Centre for Cough
    Largo, Florida 33778, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 20854, United States
  • National Allergy & Asthma Research
    Charleston, South Carolina 29420, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Allergy Asthma & Sinus Center
    Greenfield, Wisconsin 53228, United States
  • Belfast City Hospital
    Belfast, BT9 7BL, United Kingdom
  • Castle Hill Hospital
    Cottingham, HU16 5JQ, United Kingdom
  • University Hospitals of Leicester
    Leicester, LE3 9QP, United Kingdom
  • Prince Phillip Hospital
    Llanelli, SA14 8QF, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6HP, United Kingdom
  • Manchester Clinical Research Facility
    Manchester, M23 9LT, United Kingdom
  • North Tyneside General Hospital
    North Shields, NE29 8NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Apr 2020, 9 months.

Results were first posted in Aug 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 7, 2019
StartActual
Jul 10, 2019
Primary completionActual
Apr 23, 2020
CompletionActual
Apr 23, 2020
Results first posted
Aug 3, 2021
Last update
Aug 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03979638
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Jul 10, 2019
Primary completion
Apr 23, 2020
Completion
Apr 23, 2020
Results posted
Aug 3, 2021
Last update
Aug 3, 2021

Study contacts

Jacky Smith, MD, Ph.D.
principal investigator · University of Manchester

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion